- HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
- HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split
- HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV
- HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
- HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting
- HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting
- HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
- HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
- HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
- HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
More ▼
Key statistics
On Thursday, HOOKIPA Pharma Inc (HOOK:NAQ) closed at 6.32, 54.15% above the 52 week low of 4.10 set on Oct 26, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.01 |
---|---|
High | 6.37 |
Low | 5.95 |
Bid | 6.12 |
Offer | 6.50 |
Previous close | 6.02 |
Average volume | 40.55k |
---|---|
Shares outstanding | 9.90m |
Free float | 5.60m |
P/E (TTM) | -- |
Market cap | 59.57m USD |
EPS (TTM) | -5.93 USD |
Data delayed at least 15 minutes, as of Jul 25 2024 21:00 BST.
More ▼